Elevated tau PET was required as an inclusion criterion in the TRAILBLAZER-ALZ2 trial of donanemab (16), and tau PET scans were acquired in a nonrandomized subset of participants in EMERGE/ENGAGE and CLARITY-AD (14–16). This evidence concerns the gene MAPT and Alzheimer disease.